Login to Your Account

Financings Roundup

'Cysteine' Chapel, Holy Grail? Principia Funding Nets $12.5M

By Randy Osborne
Staff Writer

Tuesday, October 30, 2012
Principia Biopharma Inc.'s $12.5 million in new money should get the company's lead compound into human trials, but the company is entertaining the idea of partners to advance other prospects arising from its platform that develops reversible, tightly binding covalent therapies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription